# Cicaderma Efficacy vs Standard Care of Sites in Preventing Radiodermatitis in Non-metastatic Breast Cancer Patients

> **NCT04300829** · PHASE3 · UNKNOWN · sponsor: **Centre Leon Berard** · enrollment: 248 (estimated)

## Conditions studied

- Breast Adenocarcinoma
- Radiation Dermatitis
- Radiation Toxicity

## Interventions

- **DRUG:** cicaderma + simple hygiene rules
- **OTHER:** Simple hygiene rules and a maximum of one topical treatment

## Key facts

- **NCT ID:** NCT04300829
- **Lead sponsor:** Centre Leon Berard
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2020-06-06
- **Primary completion:** 2022-09-09
- **Final completion:** 2022-10-09
- **Target enrollment:** 248 (ESTIMATED)
- **Last updated:** 2021-02-04


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04300829

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04300829, "Cicaderma Efficacy vs Standard Care of Sites in Preventing Radiodermatitis in Non-metastatic Breast Cancer Patients". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT04300829. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*